ArticleCurrent oncology (Toronto, Ont.)2018
Standardizing biomarker testing for Canadian patients with advanced lung cancer.
Article in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years.Current oncology (Toronto, Ont.) · 2023Trial
- Cell-free tumour DNA in bronchoalveolar lavage: a proof of concept study.ERJ open research · 2026Article
- Fusion of Clinical and Deep Learning Features for Predicting Pembrolizumab Monotherapy Response in Advanced Non-Small Cell Lung Cancer.Journal of clinical medicine · 2026Article
- Exploring Cancer Patients' and Caregivers' Perspectives and Knowledge Regarding Biomarker Testing in Canada.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Article
- Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence.Current oncology (Toronto, Ont.) · 2024Article
- Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre.Current oncology (Toronto, Ont.) · 2024Article
- Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma.Frontiers in oncology · 2024Review
- New insights into the biology and development of lung cancer in never smokers-implications for early detection and treatment.Journal of translational medicine · 2023Review
- Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.Current oncology (Toronto, Ont.) · 2023Article
- Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study.Current oncology (Toronto, Ont.) · 2022Observational
- Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).Journal of clinical pathology · 2022Article
- Performance of an RNA-Based Next-Generation Sequencing Assay for Combined Detection of Clinically Actionable Fusions and Hotspot Mutations in NSCLC.JTO clinical and research reports · 2022Article
- Canadian Consensus Recommendations on the Management ofCurrent oncology (Toronto, Ont.) · 2021Article
- Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood.NPJ genomic medicine · 2021Article
- Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2020Article
- Consensus recommendations for optimizing biomarker testing to identify and treat advancedCurrent oncology (Toronto, Ont.) · 2020Article
- Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (nsclc) has significantly improved patient survival rates and quality of life. Biomarker testing for patients newly diagnosed with nsclc, as well as for patients progressing after treatment with epidermal growth factor receptor (
methodsA group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for
resultsThe standard of care must include the incorporation of testing for novel biomarkers as they become available, as it will be difficult for national guidelines to keep pace with technological advances in this area.
conclusionsCanadian patients with nsclc should be treated equally; the minimum standard of care is defined in this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.